Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495384 | 1.00 | HTT (0.46) | HTTCYP3A4HPGDMEN1CYP1A2 | |
| SCHEMBL1905387 | 0.92 | HTT (0.46) | HTTCYP3A4HPGDMEN1CYP1A2 | |
| SCHEMBL29997409 | 0.83 | POLB (0.46) | HPGDCYP2C19SMN1; SMN2POLBAPEX1 | |
| SCHEMBL690412 | 0.83 | POLB (0.46) | HPGDCYP2C19SMN1; SMN2POLBAPEX1 | |
| SCHEMBL2630704 | 0.83 | POLB (0.46) | HTTHPGDCYP2C19SMN1; SMN2POLB | |
| SCHEMBL30000050 | 0.83 | HTT (0.52) | HTTCYP3A4HPGDMEN1CYP1A2 | |
| SCHEMBL3141818 | 0.83 | HTT (0.52) | HTTCYP3A4HPGDMEN1CYP1A2 | |
| SCHEMBL2273686 | 0.83 | HTT (0.52) | HTTCYP3A4HPGDMEN1CYP1A2 | |
| SCHEMBL8709902 | 0.82 | CA1 (0.53) | HPGDMEN1KMT2ASMN1; SMN2PIK3CA | |
| SCHEMBL9533708 | 0.81 | HPGD (0.50) | HTTCYP3A4HPGDMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0188194-B1 | AMINOACRYLIC ACID DERIVATIVES | BAYER AG (DE) | 1990-07-04 | — | — | EP | claimed |
| EP-0188194-A2 | Aminoacrylic acid derivatives | BAYER AG (DE) | 1986-07-23 | — | — | EP | claimed |
| EP-4630403-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121129-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| CN-114805366-A | Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors | 百济神州有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110267959-B | Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors | 百济神州有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
| US-11136323-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2021-10-05 | — | — | US | disclosed |
| US-20050187387-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-08-25 | — | — | US | disclosed |
| EP-0807629-B1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6191164-B1 | POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| US-6071953-A | Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-06 | — | — | US | disclosed |
| EP-0860440-A1 | Sulfonamido substituted chromane derivatives with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
| EP-0188194-B1 | AMINOACRYLIC ACID DERIVATIVES | BAYER AG (DE) | 1990-07-04 | — | — | EP | disclosed |
| US-4695646-A | OXYQUINOLINECARBOXYLIC ACID INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | disclosed |
| EP-0188194-A2 | Aminoacrylic acid derivatives | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3CA | HTT 3689/4885CYP3A4 1948/4885HPGD 1796/4885 |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2483/4885CYP3A4 3494/4885HPGD 861/4885 |
| US-11136323-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | HTT 3445/4885CYP3A4 2244/4885HPGD 1861/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2483/4885CYP3A4 3494/4885HPGD 861/4885 |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | HTT 3524/4885CYP3A4 2038/4885HPGD 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.